Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET
**Dosage:** Tablet :Adults:One tablet three times daily.Syrup :Children 6 to 12 years:Half teaspoonful 6 hourly.Adults:One teaspoonful 6 hourly.
ORAL
Medical Information
**Indications:** It is indicated in nasal and respiratory congestion, common cold, acute sinusitis, allergic rhinitis.
**Contraindications:** This formula is contraindicated in patients exhibiting hypersensitivity to any of the components. Antihistamine are contraindicated in patients receiving monoamine oxidase inhibitors since these agents prolong and intensify the anticholinergic effects of anti-histamines. Antihistamines should not be used to treat lower respiratory tract symptoms. Sympathomimetic preparations are contraindicated in patients with severe hypertension, severe coronary artery disease and patients receiving MAO inhibitor therapy due to potentiation of the pressor effects of pseudoephedrine.
R06AB52
dexchlorpheniramine, combinations
Manufacturer Information
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
SUNWARD PHARMACEUTICAL SDN BHD
Active Ingredients
Documents
Package Inserts
Polarine Tablet.pdf
Approved: January 14, 2022